1. Search Result
Search Result
Results for "

Advanced glycation

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

2

Peptides

13

Natural
Products

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14892A

    LC15-0444 tartrate

    Dipeptidyl Peptidase Metabolic Disease
    Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications .
    Gemigliptin tartrate
  • HY-N7628

    Toralactone 9-O-β-D-gentiobioside

    Endogenous Metabolite Metabolic Disease
    Cassiaside C (Toralactone 9-O-β-D-gentiobioside) is a naphthopyrone isolated from the seed of Cassia tora and has inhibitory activity on advanced glycation end products (AGE) formation in vitro .
    Cassiaside C
  • HY-N0033
    Poliumoside
    2 Publications Verification

    Aldose Reductase Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Poliumoside, a caffeoylated phenylpropanoid glycoside, is isolated from Brandisia hancei stems and leaves. Poliumoside is an advanced glycation end product (AGE) formation and rat lens aldose reductase (RLAR) inhibitor, with IC50s of 19.69 and 8.47 μM, respectively. Poliumoside also has antiinflammatory and antioxidant activity .
    Poliumoside
  • HY-N7426

    3-Deoxy-D-glucosone

    GLP Receptor Metabolic Disease
    3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes .
    3-Deoxyglucosone
  • HY-106024B
    Alagebrium chloride
    1 Publications Verification

    ALT711

    Endogenous Metabolite Metabolic Disease
    Alagebrium chloride (ALT711) is an advanced glycation end product (AGE) inhibitor.
    Alagebrium chloride
  • HY-B1745
    Pyridoxylamine
    2 Publications Verification

    Pyridoxylamine is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions.
    Pyridoxylamine
  • HY-B1745A
    Pyridoxylamine dihydrochloride
    2 Publications Verification

    Pyridoxylamine dihydrochloride is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions .
    Pyridoxylamine dihydrochloride
  • HY-N4089

    Aldose Reductase Metabolic Disease
    Quercetin 3-gentiobioside is isolated from A. iwayomogi, AR and AGE formation inhibitor, demonstrates biological activities against Aldose reductase (AR) and the formation of advanced glycation endproducts (AGEs) .
    Quercetin 3-gentiobioside
  • HY-76383

    Others Metabolic Disease Inflammation/Immunology
    LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes . LR-90 is also used in the research of diabetic animal model .
    LR-90
  • HY-14892

    LC15-0444

    Dipeptidyl Peptidase Metabolic Disease
    Gemigliptin (LC15-0444 ) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin exhibits potent anti-glycation properties. Gemigliptin can be used for the research of advanced glycation end products (AGE)-related diabetic complications .
    Gemigliptin
  • HY-N12071

    Others Others
    Lucidin-ω-Me ether (Compound 2) can be isolated from the roots of Knoxia valerianoides. Lucidin-ω-Me ether inhibits the advanced glycation end products (AGEs) formation in vitro(IC50: 62.79 μM) .
    Lucidin-ω-Me ether
  • HY-113033A

    Others Neurological Disease
    Pentosidine TFA is a fluorescent advanced glycation end product (AGE) and crosslink. Pentosidine can serve as a biomarker for non-enzymatic modification of long-lived proteins by the Maillard reaction, providing insight into the overall role of the Maillard reaction in aging and disease .
    Pentosidine TFA
  • HY-N7069

    Others Cancer
    4-Isopropylbenzyl alcohol is a chemical composition of the essential oils from the leaves and flowers of Camellia nitidissima. C. nitidissima possess multiple biological activities including antioxidant activity, anticancer activity, and cytotoxicity as well as inhibiting the formation of advanced glycation end-products .
    4-Isopropylbenzyl alcohol
  • HY-N8375

    Others Metabolic Disease
    Sieboldin is a dihydrochalcone, which inhibits the production of advanced glycation end products (AGE) produced by bovine serum albumins (BSA), has free radical scavenging activity and cytotoxicity in cancer cell lines, and is also used to capture of methylglyoxal (MGO) from Malus baccata .
    Sieboldin
  • HY-50682
    Azeliragon
    Maximum Cited Publications
    9 Publications Verification

    TTP488; PF-04494700

    Amyloid-β Neurological Disease
    Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .
    Azeliragon
  • HY-N0022
    Isoacteoside
    3 Publications Verification

    Isoverbascoside

    Others Metabolic Disease
    Isoacteoside is a natural compound which exhibit significant inhibition of advanced glycation end product formation with IC50 values of 4.6-25.7 μM, compared with those of aminoguanidine (IC50=1,056 μM) and quercetin (IC50=28.4 μM) as positive controls.
    Isoacteoside
  • HY-114883

    L-Homocarnosine; γ-Aminobutyryl-L-histidine

    GABA Receptor Endogenous Metabolite Neurological Disease Inflammation/Immunology
    Homocarnosine is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects .Homocarnosine has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .
    Homocarnosine
  • HY-114883A

    L-Homocarnosine TFA; γ-Aminobutyryl-L-histidine TFA

    GABA Receptor Endogenous Metabolite Neurological Disease
    Homocarnosine TFA is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine TFA is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects . Homocarnosine TFA has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .
    Homocarnosine TFA
  • HY-P2268
    RAGE antagonist peptide
    2 Publications Verification

    Amyloid-β Inflammation/Immunology Cancer
    RAGE antagonist peptide is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide (RAP) possesses anti-tumor and anti-inflammatory activities .
    RAGE antagonist peptide
  • HY-N6883

    Aldose Reductase Metabolic Disease
    6-Methoxytricin (Compound 6) is an flavonoid isolated from Artemisia iwayomogi. 6-Methoxytricin (Compound 6) is an inhibitor on aldose reductase (AR) and advanced glycation endproduct (AGE) formation activities with IC50 values of 30.29 μM and 134.88 μM, respectively. 6-Methoxytricin (Compound 6) has potential as an anti-diabetic complications agent .
    6-Methoxytricin
  • HY-N4170
    Chebulic acid
    1 Publications Verification

    Others Metabolic Disease
    Chebulic acid, a phenolcarboxylic acid compound isolated from Terminalia chebula, has potent anti-oxidant activity, which breaks the cross-links of proteins induced by advanced glycation end-products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress and renal damage, supporting its beneficial effect in diabetic nephropathy .
    Chebulic acid
  • HY-P2268A
    RAGE antagonist peptide TFA
    2 Publications Verification

    Amyloid-β Inflammation/Immunology Cancer
    RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory activities .
    RAGE antagonist peptide TFA
  • HY-141537
    ABR-238901
    4 Publications Verification

    Toll-like Receptor (TLR) Inflammation/Immunology
    ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research .
    ABR-238901
  • HY-129611

    Apoptosis Inflammation/Immunology Cancer
    Bromelain is an anti-inflammatory agent derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway . Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death .
    Bromelain
  • HY-146619

    Amyloid-β Serotonin Transporter Neurological Disease
    RAGE/SERT-IN-1 is a potent and orally active advanced glycation end products (RAGE) and serotonin transporter (SERT) inhibitor with IC50s of 8.26 μM and 31.09 nM, respectively. RAGE/SERT-IN-1 exhibits significant neuroprotective effect against Aβ25-35-induced neuronal damage and alleviates depressive behavior of mice. RAGE/SERT-IN-1 can be used for researching the comorbidity of Alzheimer's disease and depression .
    RAGE/SERT-IN-1
  • HY-124750

    TNF Receptor Interleukin Related Toll-like Receptor (TLR) Reactive Oxygen Species Cardiovascular Disease Inflammation/Immunology
    NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research .
    NecroX-7
  • HY-147329

    Others Metabolic Disease
    RAGE 229 is an orally active ctRAGE-DIAPH1 inhibitor. RAGE 229 can inhibit the intracellular RAGE signaling by inhibiting the interaction between the cytoplasmic tail of RAGE(ctRAGE) and Diaphanous-1(DIAPH1) .
    RAGE 229

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: